H

Hospital Taiping | Clinical Research Centre

Research site

(Unclaimed)

Location

1ST FLOOR, CME HALL, HOSPITAL TAIPING, TAIPING, Perak, Malaysia

Site insights

Top conditions

Top treatments

Relamorelin

Pimodivir

Linagliptin

Lumicitabine

BI 690517

Aldosterone bloCkade

Mezagitamab

Sisunatovir

NNC0487-0111

PF-04634817

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 25 total trials

New

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity (HF-POLARIS)

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or He...

Begins enrollment this month

Obesity

Heart Failure

Drug: Placebo

Drug: NNC0487-0111

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complex...

Enrolling

Kidney Disease

Drug: Mezagitamab

Drug: Placebo

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study....

Enrolling

Kidney Disease, Chronic

Drug: Placebo matching BI 690517

Drug: Empagliflozin